BioWorld

Jan. 16, 2002

Valentis Scales Back Preclinical Programs, Staff To Save Money

An accumulation of products in preclinical development has forced Burlingame, Calif.-based Valentis Inc. to scale back its work force by about 42 percent. Read More

LION Purchasing NetGenics In Stock Deal Worth $17.6M

Synsorb Selling Certain Assets Following Lead-Product Failure

Other News To Note

Correction

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...